VIR-2218
VIR-2218-1001-PEG-IFNα
Phase 2 small_molecule completed
Quick answer
VIR-2218 for Chronic Hepatitis B is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Chronic Hepatitis B
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed